Form 4: Bolt Biotherapeutics Director Granted Stock Options Following 1-for-20 Reverse Stock Split

Bolt Biotherapeutics, Inc. Director Nicole Onetto was granted 1,100 stock options at an exercise price of $6.4, reflecting a recent 1-for-20 reverse stock split.

Summary

• Nicole Onetto, a Director of Bolt Biotherapeutics, Inc. (BOLT), was granted stock options on May 27, 2025.
• The grant involved 1,100 derivative securities (stock options) to purchase common stock.
• The exercise price for these options is $6.4 per share.
• The options expire on May 26, 2035.
• A 1-for-20 reverse stock split was effected by the company on June 6, 2025, and all reported share and exercise price amounts reflect this split.
• Prior to the reverse stock split, the grant was for 22,000 shares at an exercise price of $0.3200 per share.
• The options will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, contingent on continuous service.
• Full vesting of the options will occur upon a change in control of the Issuer.

Sentiment

Score: 3

Explanation: The grant of options to a director is a positive for aligning interests, but the underlying reason for the reverse stock split (often a low stock price) is a significant negative, outweighing the positive of the option grant itself.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The vesting schedule, including accelerated vesting upon a change in control, provides a clear incentive structure for the director.

Negatives

• The 1-for-20 reverse stock split, effective June 6, 2025, is often viewed negatively by the market as it typically indicates a company's stock price has fallen significantly, potentially below exchange minimums, and does not fundamentally improve the company's underlying value.

Risks

• The value of the stock options is dependent on the future performance of Bolt Biotherapeutics' common stock exceeding the $6.4 exercise price.
• Vesting of the options is subject to the director's continuous service through the specified vesting dates, meaning the options could be forfeited if service ceases before vesting.
• The reverse stock split itself carries a risk of further stock price decline or reduced liquidity, as historical data suggests companies undergoing reverse splits often experience continued share price weakness.

Future Outlook

The document primarily reports a past insider transaction and a corporate action (reverse stock split), along with future vesting conditions for the granted options. It does not provide a general future outlook for the company's operational or financial performance.

Industry Context

Form 4 filings are standard disclosures for insider transactions. The grant of stock options to directors is a common practice across industries, including biotechnology, to align management and board interests with shareholder value. The reverse stock split is a corporate action often undertaken by companies, particularly in the volatile biotech sector, whose stock prices have fallen significantly, frequently to maintain exchange listing requirements or improve market perception. This is not an uncommon occurrence for smaller biotech companies facing R&D challenges or funding pressures.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation widely used across industries, including biotech, to incentivize performance and align interests.
• The 1-for-20 reverse stock split is a specific corporate action, often taken by companies whose stock price has fallen significantly, which is not uncommon in the volatile biotech industry where companies are often pre-revenue and dependent on R&D success and funding. While common, it is generally viewed as a negative signal by the market, as it does not change the underlying value of the company.

Corporate Governance

Related Party Transactions

• The grant of stock options to Nicole Onetto, a Director of Bolt Biotherapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of shares outstanding and proportionally increases the share price, which can be perceived negatively as it often follows significant stock price declines. The option grant dilutes existing shareholders slightly upon exercise but aligns director incentives.
• Management/Directors: Nicole Onetto, as a director, benefits from the potential upside of the stock options, aligning her financial interests with the company's performance.

Next Steps

• The stock options will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, subject to continuous service.
• Full vesting will occur upon a change in control of the Issuer.

Key Dates

Recommendation

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Stock Option Grant, Director Compensation, Reverse Stock Split, Equity Compensation, Biotechnology, Insider Transaction, Corporate Governance